Acme United Q2 2026 Earnings: EPS and Revenue Beat on MyMedic Growth and Margin Expansion

• Acme United reported a significant Q2 2026 earnings beat driven by a 16% YoY revenue surge to $62.7M, largely aided by the MyMedic acquisition.
• The company expanded gross margins to 42.6% and management expects continued margin recovery as tariff pressures ease and lower-cost inventory replaces higher-tariff stock.
• Diluted EPS reached $1.22, surpassing estimates of $0.81 by nearly 51%, prompting an 11.92% surge in share price to near a 52-week high of $51.88.
• Investors should monitor risks including elevated SG&A expenses at 32% of sales, ongoing tariff headwinds, and uneven geographic performance, particularly in Canada.

Acme United Corporation (ACU) delivered a robust set of financial results for the second quarter of 2026, significantly outperforming market expectations across both revenue and profitability metrics. The company reported diluted earnings per share (EPS) of $1.22, a figure that represents a substantial 50.6% surprise against the consensus estimate of $0.81 . This strong performance was mirrored in the top line, where revenue reached $62.72 million, beating forecasts of $58.08 million by nearly 8% . The market responded swiftly to the data, with shares surging approximately 11.92% to trade near a 52-week high of $51.88 immediately following the release .

The financial outperformance was not merely a result of general market tailwinds but was driven by specific operational successes and strategic acquisitions. Revenue growth was robust at 16% year-over-year, a figure that provides a clear picture of the company's expanding footprint . A significant portion of this increase was bolstered by the integration of the MyMedic acquisition . When excluding the contribution from MyMedic, organic growth stood at a solid 8%, indicating that the core business remains healthy and capable of independent expansion . This dual engine of organic growth and strategic acquisition has allowed Acme United to scale effectively while maintaining operational discipline.

Profitability metrics further underscore the strength of the quarter, with gross margins expanding to 42.6% from 41.0% in the prior year period . This improvement highlights effective cost management and enhanced pricing power within the company's product lines. The expansion in margins suggests that Acme United is successfully navigating the complex landscape of supply chain costs and tariff impacts that have weighed on many industrial and consumer goods sectors recently .

How Is the MyMedic Acquisition Driving Growth?

The integration of MyMedic has emerged as a central pillar of Acme United's recent growth trajectory, providing both immediate revenue boosts and long-term strategic opportunities. The acquisition has contributed significantly to the 16% year-over-year sales increase, serving as a key differentiator in the company's quarterly performance . Management is actively working to expand MyMedic’s distribution channels, moving beyond its initial direct-to-consumer focus into mass retail environments . This strategic shift is expected to unlock new customer bases and drive further volume growth as the brand gains visibility in broader retail settings.

The successful integration of MyMedic also demonstrates Acme United's ability to execute on its M&A strategy, adding value beyond simple financial consolidation. By leveraging existing operational infrastructure and distribution networks, the company aims to maximize the synergies derived from the acquisition . This approach not only accelerates growth but also helps to offset potential integration costs, contributing to the overall margin expansion observed in Q2 . The focus on mass retail expansion is anticipated to yield strong results in the fourth quarter, driven by seasonal demand patterns and the broadened reach of the MyMedic brand .

What Are the Key Risks and Forward Outlook?

Despite the positive results, several risks remain that investors should carefully monitor in the coming quarters. Selling, General, and Administrative (SG&A) expenses are currently elevated at 32% of sales, which could potentially pressure net income if not managed effectively . Additionally, the company faces ongoing headwinds from tariffs, freight costs, and currency fluctuations, all of which introduce volatility into the cost structure . Geographic performance was uneven during the quarter, with Canada lagging behind other regions, highlighting potential regional vulnerabilities .

Looking ahead, management provided positive outlook commentary, with CEO Johnsen anticipating continued margin recovery throughout the remainder of the year . This expectation is based on the gradual replacement of higher-tariff inventory with lower-cost stock as tariff pressures ease . The company expects strong Q4 profitability driven by seasonal demand, which should further support revenue and margin growth . However, analysts forecast a more modest EPS of $0.72 for the upcoming quarter ending September 2026, suggesting that the extraordinary performance in Q2 may not be easily repeatable . Investors should remain vigilant regarding the company's ability to maintain margin expansion amidst a potentially challenging macroeconomic environment .

Acme United's financial health is further supported by robust liquidity and operational efficiency metrics. The company maintains a current ratio of 3.23, indicating strong short-term liquidity compared to the industry average of 2.33 . Its asset turnover of 1.14 is significantly higher than the industry average of 0.54, suggesting efficient use of assets to generate sales . These metrics provide a buffer against potential operational disruptions, although the slight decline in trailing twelve-month EPS of 6.32% warrants attention . The company has maintained a stable dividend policy, paying $0.16 per share quarterly, which offers income stability but lags behind the industry average growth rate .